Results 51 to 60 of about 16,268 (199)

All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches

Antibiotics, 2023
In light of rising antimicrobial resistance and a decreasing number of antibiotics with novel modes of action, it is of utmost importance to accelerate development of novel treatment options.
Kashaf Khalid, Katharina Rox
doaj   +1 more source

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) [PDF]

, 2016
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
A, A, A, A, A, A, A, A, A, A, A, A, A, AA, AC, AH, AJ, AK, AK, AM, AW, B, B, B, B, BJ, C, C, C, C, CA, CA, CE, D, D, D, DG, DP, E, EA, EE, F, F, F, F, FA, FM, FM, G, G, G, G, G, G, G, GA, GP, H, H, H, H, HAS, HE, I, I, I, I, IJ, J, J, JA, JE, JF, JG, JJ, JJ, JL, JR, JR, JR, JV, K, K, K, K, KA, KC, KYY, L, LJ, M, M, M, M, M, M, M, M, M, M, M, M, M, MA, MA, MA, MA, MC, MG, MM, MN, MP, N, N, NT, O, OR, P, P, P, P, PF, PK, R, R, R, R, R, R, R, RB, RG, RM, RR, RR, RS, RV, S, S, S, S, S, S, S, S, S, Sartelli, SJ, SK, SK, SM, SR, SR, SY, T, T, TL, TM, V, V, VG, VN, W, W, W, WL, WR, Y, YF, YH, YR, YS, Z, ZJ   +173 more
core   +4 more sources

Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools

Frontiers in Microbiology, 2023
IntroductionAntimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often the last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative ...
Gil Verschelden, Gil Verschelden, Maxim Noeparast, Anke Stoefs, Eveline Van Honacker, Kristof Vandoorslaer, Laura Vandervore, Margo Olbrecht, Kathleen Van Damme, Thomas Demuyser, Thomas Demuyser, Denis Piérard, Ingrid Wybo   +12 more
doaj   +1 more source

identifying allosteric networks to fight antibiotics resistance [PDF]

, 2018
The rise of multi-drug resistance in bacterial pathogens is one of the grand challenges facing medical science. A major concern is the speed of development of β-lactamase-mediated resistance in Gram-negative species, thus putting at risk the efficacy of ...
Afsharikho, Hamidreza, Barnes, Melissa D., Bonomo, Robert A., Galdadas, Ioannis, Gervasio, Francesco L., Haider, Shozeb, Healy, Jess, Lovera, Silvia, Pérez-Hernández, Guillermo, Woodford, Neil   +9 more
core   +1 more source

The Rapid CarbaLux Combination Test to Uncover Bacterial Resistance and Heteroresistance Prior to Antibiotic Treatment

Diagnostics
Background/Objectives: In this proof-of-concept study, the objective was to evaluate the phenotypic CarbaLux combination rapid test in terms of guiding the therapy of infections caused by multidrug-resistant Gram-negative bacteria with carbapenemase ...
Hans Rudolf Pfaendler, Hans-Ulrich Schmidt   +1 more
doaj   +1 more source

Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. [PDF]

PLoS ONE, 2015
β-Lactamase inhibition is an important clinical strategy in overcoming β-lactamase-mediated resistance to β-lactam antibiotics in Gram negative bacteria.
Nikhil P Krishnan, Nhu Q Nguyen, Krisztina M Papp-Wallace, Robert A Bonomo, Focco van den Akker   +4 more
doaj   +1 more source

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. [PDF]

, 2016
This study aimed to investigate the pharmacokinetics (PK), safety, and tolerability of a single dose of ceftazidime-avibactam in pediatric patients. A phase I, multicenter, open-label PK study was conducted in pediatric patients hospitalized with an ...
Armstrong, Jon, Arrieta, Antonio, Bishai, Raafat, Bradley, John S, Das, Shampa, Delair, Shirley, Edeki, Timi, Holmes, William C, Li, Jianguo, Moffett, Kathryn S, Mukundan, Deepa, Perez, Norma, Romero, José R, Speicher, David, Sullivan, Janice E, Zhou, Diansong   +15 more
core  

WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases [PDF]

, 2017
Background: Several diazabicyclooctanes (DBOs) are under development as inhibitors of Class A and C -lactamases. Inhibition of OXA (Class D) carbapenemases is variable, with those of Acinetobacter spp. remaining notably resistant. We describe a novel DBO,
Anna Vickers, Clinical and Laboratory Standards Institute, David M. Livermore, Neil Woodford, Shazad Mushtaq   +4 more
core   +1 more source

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source

Antimicrobial Resistance: We Must Pursue a Collaborative, Global Approach and Use a "One Health" Approach. [PDF]

, 2019
Treating infection is a key part of the work of most clinicians [...]
Lipman, J, Lonsdale, DO
core   +1 more source